Oculis
About Oculis
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Company Metrics
- Employees: 11-50
- Monthly Visits: 762
- Tech Stack: 21 active products
Financial Information
- Estimated Revenue:
- Total Funding: 94355910 USD
- Last Funding: 57000000 USD (Series C)
- Funding Status: Late Stage Venture
Technology Stack
Oculis actively uses 21 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Pharmaceutical
Headquarters: Reykjavík, Gullbringusysla, Iceland